RECOMBITEK® delivers advanced and proven technology.
All RECOMBITEK® Brand Equine Vaccines owe at least part of their effectiveness to advanced science called recombinant canarypox-vectored vaccine technology. The combination vaccine, RECOMBITEK rWNV-EWT also uses more traditional killed virus technology for its Eastern equine encephalitis (EEE) and Western equine encephalitis (WEE) as well as the tetanus toxoid fraction.
The recombinant technology used in RECOMBITEK vaccines stimulates both arms of the horse’s immune system (circulating antibodies and cell-mediated immunity),1,2 and uses only the proteins needed by the horse to stimulate immunity.
 |
How to use RECOMBITEK rWNV-EWT.
- RECOMBITEK rWNV-EWT is safe for horses as young as 4 months of age3
- Provides four of the five core vaccinations4 in a single annual dose.*,3
|
| RECOMBITEK rWNV-EWT Usage |
| Dose |
Age |
Administration |
Desiccant (cake) |
Diluent (liquid) |
Package |
2 mL
annual* |
4 months and older |
Intramuscular (IM) |
Viral-vectored
recombinant WNV |
EEE, WEE
killed virus;
tetanus toxoid |
10 x 1 dose
5 x 5 dose |
|
*For previously vaccinated horses. Unvaccinated horses require a primary two-dose vaccination, four to six weeks apart.3 |
 |
How to use RECOMBITEK® Equine rWNV vaccine.
- RECOMBITEK Equine rWNV vaccine is safe for use in horses 2 to 4 months of age and older5
- Labeled for annual revaccination with a single dose**,6
- Horses are fully protected 14 days after two-dose series;7 schedule annual vaccinations in advance of the mosquito season
|
| **Following initial two-dose series. |
| RECOMBITEK Equine rWNV Usage |
| Dose |
Age |
Administration |
Desiccant (cake) |
Diluent (liquid) |
Package |
1 mL
annual* |
2 to 4 months
and older |
Intramuscular (IM) |
Viral-vectored
recombinant WNV |
Sterile diluent
(adjuvant) |
10 x 1 dose
5 x 5 dose |
|
*For previously vaccinated horses. Unvaccinated horses require a primary two-dose vaccination, four to six weeks apart.6 |
 |
How to use RECOMBITEK rFLU vaccine.
- RECOMBITEK rFLU vaccine is safe for use in foals 4 months of age and older8
- Labeled for annual revaccination with a single dose*,8
- Significantly reduces viral shedding8,9
|
| RECOMBITEK Equine Influenza Virus Vaccine Usage |
| Dose |
Age |
Administration |
Desiccant (cake) |
Diluent (liquid) |
Package |
2 mL
annual* |
4 months and older |
Intramuscular (IM) |
Viral-vectored
recombinant |
Sterile diluent
(adjuvant) |
10 x 1 dose
5 x 5 dose |
|
*For previously vaccinated horses. Unvaccinated horses require a primary two-dose vaccination, five weeks apart.8 |
1Siger L, et al. Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses. American Journal of Veterinary Research 2004;65(11):1459-1462.
2El Garch H, Minke J, et al. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse. Vet Immunol Immunopathol 2008;123:230-239.
3RECOMBITEK rWNV-EWT product label.
4Guidelines for Vaccination of Horses. American Association of Equine Practitioners. Available at: http://www.aaep.org/vaccination_guidelines.htm. Accessed August 3, 2009.
5Data on file at Merial. Study 02-067.
6RECOMBITEK Equine rWNV vaccine product label.
7Data on file at Merial. Study 02-092.
8RECOMBITEK Equine Influenza Virus vaccine product label.
9Paillot R, et al. Antibody and IFN-γ responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus. Vet Immuno Immunopathol 2006;112:225-233.
®RECOMBITEK is a registered trademark and ™the HORSE HEAD LOGO is a trademark of Merial Limited.
